Yale Faculty to Direct PTSD Study Business New Haven 10/03/2005 BNH NEW HAVEN - The Yale School of Medicine will direct a $6.9 million nationwide study into the effectiveness of an anti-psychotic medication, risperidone, for veterans with chronic, military service-related post-traumatic stress disorder (PTSD). Thirteen percent of all VA mental health costs, or $274 million, is spent to care for veterans with PTSD. Currently, there are only two medication treatments approved by the U.S. Food & Drug Administration for the treatment of PTSD. John Krystal, MD, professor in the Department of Psychiatry at Yale School of Medicine and Robert Rosenheck, MD, also a professor of psychiatry at Yale, will direct the study from the VA Connecticut Healthcare System in West Haven. As part of the study 400 veterans with chronic, military service-related PTSD will be enrolled at 20 VA hospitals from across the country over a two-year period.